Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II randomized double-blind active-controlled study of 24-valent pneumococcal conjugate vaccine in adults
CTR20252200Phase 2Active
- Sponsor
- Sino Biopharmaceutical Limited
- Start
- Jun 2025
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Reinovax PCV24 in pneumococcal disease, sponsored by Sino Biopharmaceutical Limited. Started Jun 2025; status: active.
02
Drugs
Reinovax PCV24
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20252200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252200.